HFE siRNA (Mouse)
Cat# MBS827526-15nmol
Size : 15nmol
Brand : MyBiosource
HFE siRNA – Hereditary Hemochromatosis Protein Homolog (Mouse)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS827526MBS827526 is an siRNA targeting HFE. Also known as HFE siRNA (Mouse). Reactive in Mouse. Host: Synthetic. siRNA to inhibit HFE expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
HFE, siRNA
Full Product Name
HFE siRNA (Mouse)
Product Gene Name
HFE sirna
Product Synonym Names
MR2; Hereditary hemochromatosis protein homolog
Host
Synthetic
Species Reactivity
Mouse
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
HFE siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
40,534 Da
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse HFE gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for HFE sirna
RNA Interference (RNAi)
Other Notes
Small volumes of HFE sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for HFE. It may not necessarily be applicable to this product.
NCBI Official Full Name
hereditary hemochromatosis protein homolog
NCBI Official Synonym Full Names
hemochromatosis
NCBI Official Symbol
Hfe
NCBI Official Synonym Symbols
MR2
UniProt Protein Name
Hereditary hemochromatosis protein homolog
Protein Family
Hereditary hemochromatosis protein
UniProt Gene Name
Hfe
UniProt Synonym Gene Names
Mr2
UniProt Entry Name
HFE_MOUSE
NCBI Protein Information
hereditary hemochromatosis protein homolog
UniProt Comments for HFE
HFE: Binds to transferrin receptor (TFR) and reduces its affinity for iron-loaded transferrin. Defects in HFE are a cause of hemochromatosis (HFE). A disorder of iron metabolism characterized by iron overload. Excess iron is deposited in a variety of organs leading to their failure, and resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis, and hypogonadotropic hypogonadism. Severe effects of the disease usually do not appear until after decades of progressive iron loading. Defects in HFE are associated with variegate porphyria (VP). Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. VP is the most common form of porphyria in South Africa. It is characterized by skin hyperpigmentation and hypertrichosis, abdominal pain, tachycardia, hypertension and neuromuscular disturbances. High fecal levels of protoporphyrin and coproporphyrin, increased urine uroporphyrins and iron overload are typical markers of the disease. Iron overload due to HFE mutations is a precipitating or exacerbating factor in variegate porphyria. Defects in HFE are associated with susceptibility to microvascular complications of diabetes type 7 (MVCD7). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Belongs to the MHC class I family. 11 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral
Cellular Component: recycling endosome; membrane; perinuclear region of cytoplasm; apical part of cell; early endosome; integral to membrane; plasma membrane; cytoplasmic vesicle; MHC class I protein complex
Molecular Function: peptide antigen binding; antigen binding; receptor binding
Biological Process: antigen processing and presentation; iron ion homeostasis; antigen processing and presentation of peptide antigen via MHC class I; immune system process; positive regulation of T cell mediated cytotoxicity; immune response; hormone biosynthetic process
Disease: Alzheimer Disease
Show more Protein type: Membrane protein, integral
Cellular Component: recycling endosome; membrane; perinuclear region of cytoplasm; apical part of cell; early endosome; integral to membrane; plasma membrane; cytoplasmic vesicle; MHC class I protein complex
Molecular Function: peptide antigen binding; antigen binding; receptor binding
Biological Process: antigen processing and presentation; iron ion homeostasis; antigen processing and presentation of peptide antigen via MHC class I; immune system process; positive regulation of T cell mediated cytotoxicity; immune response; hormone biosynthetic process
Disease: Alzheimer Disease
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with HFE sirna
| Reference Product | PubMed Publications |
|---|---|
| Tfr2 sirna | >210 publications with HFE and Tfr2 |
| Slc40a1 sirna | >54 publications with HFE and Slc40a1 |
| Tfrc sirna | >21 publications with HFE and Tfrc |
| Hamp2 sirna | >3 publications with HFE and Hamp2 |
| B2m sirna | >3 publications with HFE and B2m |
| Slc39a14 sirna | >2 publications with HFE and Slc39a14 |
Pathways associated with HFE sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| Iron Homeostasis Pathway antibodies | Iron Homeostasis Pathway Diagram |
Diseases associated with HFE sirna
| Disease Name | Pubmed Publications |
|---|---|
| Hemochromatosis Antibodies | >2250 publications with HFE and Hemochromatosis |
| Liver Diseases Antibodies | >576 publications with HFE and Liver Diseases |
| Fibrosis Antibodies | >179 publications with HFE and Fibrosis |
| Hepatitis C Antibodies | >169 publications with HFE and Hepatitis C |
| Nervous System Diseases Antibodies | >149 publications with HFE and Nervous System Diseases |
| Cardiovascular Diseases Antibodies | >146 publications with HFE and Cardiovascular Diseases |
| Inflammation Antibodies | >113 publications with HFE and Inflammation |
| Carcinoma, Hepatocellular Antibodies | >109 publications with HFE and Carcinoma, Hepatocellular |
| Porphyria Cutanea Tarda Antibodies | >100 publications with HFE and Porphyria Cutanea Tarda |
| Fatty Liver Antibodies | >99 publications with HFE and Fatty Liver |
Organs/Tissues associated with HFE sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Liver Antibodies | >1013 publications with HFE and Liver |
| Heart Antibodies | >152 publications with HFE and Heart |
| Bone Antibodies | >98 publications with HFE and Bone |
| Joint Antibodies | >83 publications with HFE and Joint |
| Brain Antibodies | >82 publications with HFE and Brain |
| Skin Antibodies | >59 publications with HFE and Skin |
| Spleen Antibodies | >48 publications with HFE and Spleen |
| Kidney Antibodies | >43 publications with HFE and Kidney |
| Lung Antibodies | >27 publications with HFE and Lung |
| Bone Marrow Antibodies | >22 publications with HFE and Bone Marrow |


